HK1211040A1 - New albumin binding compositions, methods and uses - Google Patents

New albumin binding compositions, methods and uses

Info

Publication number
HK1211040A1
HK1211040A1 HK15111838.6A HK15111838A HK1211040A1 HK 1211040 A1 HK1211040 A1 HK 1211040A1 HK 15111838 A HK15111838 A HK 15111838A HK 1211040 A1 HK1211040 A1 HK 1211040A1
Authority
HK
Hong Kong
Prior art keywords
methods
albumin binding
binding compositions
new albumin
new
Prior art date
Application number
HK15111838.6A
Other languages
English (en)
Chinese (zh)
Inventor
．阿布拉姆森
．榮森
．多甘
．尼格倫
Original Assignee
Affibody Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody Ab filed Critical Affibody Ab
Publication of HK1211040A1 publication Critical patent/HK1211040A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
HK15111838.6A 2007-07-31 2015-12-02 New albumin binding compositions, methods and uses HK1211040A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96261807P 2007-07-31 2007-07-31
EP07113533 2007-07-31

Publications (1)

Publication Number Publication Date
HK1211040A1 true HK1211040A1 (en) 2016-05-13

Family

ID=40057660

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111838.6A HK1211040A1 (en) 2007-07-31 2015-12-02 New albumin binding compositions, methods and uses

Country Status (11)

Country Link
US (2) US8937153B2 (hr)
EP (2) EP2190863B1 (hr)
JP (1) JP5718638B2 (hr)
CN (2) CN104710518A (hr)
AU (1) AU2008281913B2 (hr)
CA (1) CA2694139C (hr)
DE (1) DE08786222T1 (hr)
DK (1) DK2190863T3 (hr)
ES (1) ES2346178T3 (hr)
HK (1) HK1211040A1 (hr)
WO (1) WO2009016043A2 (hr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104710518A (zh) * 2007-07-31 2015-06-17 阿菲博迪公司 新白蛋白结合组合物、方法及应用
ES2548030T3 (es) * 2009-06-01 2015-10-13 Medimmune, Llc Moléculas con semividas prolongadas y usos de las mismas
WO2011110515A1 (en) * 2010-03-08 2011-09-15 Affibody Ab Immunoglobulin g fc region binding polypeptide
MX2012012383A (es) * 2010-04-30 2012-11-30 Sanwa Kagaku Kenkyusho Co Peptido para mejorar la bioestabilidad de una sustancia bioactica y sustancia bioactiva que tiene bioestabilidad mejorada.
CN110437320B (zh) * 2010-07-09 2023-10-20 阿菲博迪公司 多肽
CA2807127C (en) * 2010-08-02 2019-02-12 Leslie S. Johnson Covalent diabodies and uses thereof
EA201390450A1 (ru) 2010-09-28 2013-07-30 Амилин Фармасьютикалс, Ллк. Полипептиды с увеличенной продолжительностью действия
BR112013007388B1 (pt) * 2010-09-28 2022-01-04 Amylin Pharmaceuticals, Llc Polipeptídeo tendo domínio de ligação de albumina e leptina, seu uso no tratamento de doenças, bem como composição farmacêutica que o compreende
KR20140032356A (ko) 2010-11-26 2014-03-14 몰리큘라 파트너스 아게 설계된 안키린 반복 단백질에 대한 개선된 n-말단 캡핑 모듈
WO2012162068A2 (en) * 2011-05-21 2012-11-29 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
JP6006309B2 (ja) * 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニーＡｍｙｌｉｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｌｌｃ 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
US20140256621A1 (en) * 2011-07-08 2014-09-11 Astrazeneca Pharmaceuticals Lp Engineered poypeptides having enhanced duration of action and reduced immunogenicity
SI2817329T1 (sl) 2012-02-20 2019-04-30 Swedish Orphan Biovitrum Ab (Publ) Polipeptidi, ki se vežejo na človeški komplement c5
JP2020033372A (ja) * 2012-03-28 2020-03-05 アフィボディ・アーベー 経口投与
KR20210075191A (ko) 2012-03-28 2021-06-22 애피바디 에이비 경구투여
US20150133373A1 (en) * 2012-03-28 2015-05-14 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
EP2855509B1 (en) 2012-05-25 2018-05-02 Janssen Biotech, Inc. Non-natural consensus albumin binding domains
CN111763247A (zh) * 2012-09-25 2020-10-13 阿菲博迪公司 白蛋白结合多肽
CN104768976B (zh) 2012-10-05 2020-09-22 阿菲博迪公司 Her3结合多肽
ES2639099T3 (es) * 2012-10-25 2017-10-25 Affibody Ab Polipéptido de unión a albúmina
WO2014064238A1 (en) * 2012-10-25 2014-05-01 Affibody Ab Method for the separation of proteins containing an albumin-binding
WO2014076179A1 (en) 2012-11-14 2014-05-22 Affibody Ab New polypeptide
US9255262B2 (en) 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
USRE48805E1 (en) 2013-03-06 2021-11-02 Vision Global Holdings Ltd. Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
BR112015021681A2 (pt) 2013-03-14 2017-11-14 Daiichi Sankyo Co Ltd proteínas de ligação para pcsk9
CA2902789A1 (en) 2013-03-14 2014-09-18 The Governing Council Of The University Of Toronto Scaffolded peptidic libraries and methods of making and screening the same
BR112015021730A2 (pt) 2013-03-15 2017-08-29 Affibody Ab POLIPEPTÍDEO DE LIGAÇÃO AO FcRn, PROTEÍNA DE FUSÃO OU CONJUGADO, POLINUCLEOTÍDEO QUE CODIFICA UM POLIPEPTÍDEO, COMPOSIÇÃO, POLIPEPTÍDEO DE LIGAÇÃO AO FcRn, PROTEÍNA DE FUSÃO OU CONJUGADO E POLIPEPTÍDEO DE LIGAÇÃO AO FcRn, PROTEÍNA DE FUSÃO, CONJUGADO OU COMPOSIÇÃO PARA USO
CA2908198A1 (en) 2013-04-18 2014-10-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP2016528879A (ja) 2013-06-17 2016-09-23 アルモ・バイオサイエンシーズ・インコーポレイテッド タンパク質の同一性および安定性を評価する方法
EP3811961A1 (en) 2013-08-28 2021-04-28 IPC Research, LLC Stable polypeptides binding to human complement c5
EP3039033B1 (en) 2013-08-28 2019-06-19 Affibody AB Binding polypeptides having a mutated scaffold
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
WO2015070060A1 (en) 2013-11-11 2015-05-14 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10167322B2 (en) 2013-12-20 2019-01-01 Affibody Ab Engineered albumin binding polypeptide
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
CA2953827A1 (en) 2014-07-30 2016-02-04 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
LT3193930T (lt) 2014-09-17 2019-10-25 Affibody Ab Nauji polipeptidai
JP2017536098A (ja) 2014-10-14 2017-12-07 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１５組成物及びその使用
US10143726B2 (en) 2014-10-22 2018-12-04 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP3212226B1 (en) 2014-10-31 2020-03-18 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
NZ732978A (en) 2015-01-12 2022-01-28 Affibody Ab Il-17a-binding polypeptides
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP3291828A4 (en) 2015-05-06 2018-10-03 Alborz Mahdavi Glucose responsive insulins
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
EA037478B1 (ru) 2015-08-04 2021-04-01 Дьюк Юниверсити Генетически кодируемые внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
CN107022031A (zh) * 2016-01-29 2017-08-08 中国人民解放军军事医学科学院微生物流行病研究所 融合蛋白HSA1-Vβ1及其应用
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
CN107952080A (zh) * 2016-10-14 2018-04-24 中国科学院过程工程研究所 一种肿瘤靶向多肽-药物偶联衍生物、其制备方法及应用
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
JP2020530453A (ja) * 2017-08-09 2020-10-22 マサチューセッツ インスティテュート オブ テクノロジー アルブミン結合ペプチド結合体及びその方法
WO2019071150A1 (en) * 2017-10-06 2019-04-11 University Of Utah Research Foundation FUSION PROTEIN FOR TARGETED THERAPY OF AUTOIMMUNE DISEASE
US20200239575A1 (en) * 2017-10-06 2020-07-30 University Of Utah Research Foundation A fusion protein for targeted therapy of autoimmune disease
US11505576B2 (en) 2018-03-13 2022-11-22 Affibody Ab Polypeptides based on a scaffold
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
JP2022546525A (ja) 2019-09-02 2022-11-04 ビオテスト・アクチエンゲゼルシャフト 延長された半減期を有する第ｖｉｉｉ因子タンパク質
WO2021089695A1 (en) 2019-11-05 2021-05-14 Affibody Ab Polypeptides
US20230190881A1 (en) 2020-02-17 2023-06-22 Biotest Ag Subcutaneous administration of factor viii
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
EP4263589A1 (en) 2020-12-21 2023-10-25 Affibody AB New polypeptide
EP4291251A1 (en) 2021-02-15 2023-12-20 Affibody AB New her2-binding polypeptide
AR128475A1 (es) 2022-02-08 2024-05-15 Affibody Ab Polipéptidos y proteínas de fusión con afinidad de unión por tslp

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
FR2726471B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
DE19742706B4 (de) * 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9823071D0 (en) * 1998-10-21 1998-12-16 Affibody Technology Ab A method
GB9911287D0 (en) * 1999-05-14 1999-07-14 Affibody Technology Sweden Ab Self-assembling protein structures
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
ATE422369T1 (de) 1999-12-24 2009-02-15 Genentech Inc Verfahren und zusammensetzungen zur verlängerung der entsorgungshalbwertszeit von biowirksamen verbindungen
CN1169827C (zh) 2001-08-07 2004-10-06 沈阳三生制药股份有限公司 一种增强多肽在体内稳定性药物的生产方法及其应用
WO2003029462A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7118915B2 (en) * 2001-09-27 2006-10-10 Pieris Proteolab Ag Muteins of apolipoprotein D
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
JP5634008B2 (ja) 2004-04-06 2014-12-03 アフィボディ・アーベー 新規の使用および方法
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
CN104710518A (zh) * 2007-07-31 2015-06-17 阿菲博迪公司 新白蛋白结合组合物、方法及应用
JP5960598B2 (ja) * 2009-11-04 2016-08-02 アフィボディ・アーベー Ｈｅｒ３結合ポリペプチド

Also Published As

Publication number Publication date
EP2546261A3 (en) 2013-08-14
CN101765608A (zh) 2010-06-30
WO2009016043A3 (en) 2009-06-04
WO2009016043A2 (en) 2009-02-05
AU2008281913B2 (en) 2013-11-07
JP5718638B2 (ja) 2015-05-13
US8937153B2 (en) 2015-01-20
US10118949B2 (en) 2018-11-06
DE08786222T1 (de) 2010-11-25
CN104710518A (zh) 2015-06-17
US20100273979A1 (en) 2010-10-28
ES2346178T3 (es) 2015-11-02
CA2694139C (en) 2018-06-05
US20150158916A1 (en) 2015-06-11
EP2546261A2 (en) 2013-01-16
CN101765608B (zh) 2015-03-11
DK2190863T3 (en) 2015-11-30
JP2010534486A (ja) 2010-11-11
CA2694139A1 (en) 2009-02-05
ES2346178T1 (es) 2010-10-13
AU2008281913A1 (en) 2009-02-05
EP2190863B1 (en) 2015-09-02
EP2190863A2 (en) 2010-06-02

Similar Documents

Publication Publication Date Title
HK1211040A1 (en) New albumin binding compositions, methods and uses
HRP20181353T1 (hr) Tuberkulozni protein rv2386c, njegovi pripravci i upotreba
IL230759A0 (en) Converted acyl anilide, the pharmaceutical composition containing it and its uses
IL211284A0 (en) Antibodies binding ccr2, compositions comprising the same and uses thereof
GB0601143D0 (en) Uses, methods and compositions
IL226339B (en) Aptamers that bind to 5c, preparations containing them and their uses
EP2069401A4 (en) MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
ZA201001300B (en) Antigen-asjuvant compositions and methods
EP2076604A4 (en) GLP-2 MIMIC BODIES, POLYPEPTIDES, COMPOSITIONS, PROCESSES AND USES
ZA201005278B (en) Folates, compositions and uses thereof
GB0706077D0 (en) Methods, Compositions and uses thereof
IL205966A0 (en) Oligomer-tricyclic conjugates, compositions comprising the same and uses thereof
GB0721291D0 (en) Methods and compositions
EP2214690A4 (en) THE MELANOCORTIN RECEPTOR BINDING MIMIC BODIES, COMPOSITIONS, PROCESSES AND USES
GB0719526D0 (en) Compositions and methods
GB0819432D0 (en) Compound, composition and use
IL202996A0 (en) Anti-mcp-1 antibodies, compositions, methods and uses
GB2453860B (en) Ionizing-radiation-responsive compositions,methods and systems
HRP20150021T1 (en) Phenanthrenone compounds, compositions and methods
ZA201006443B (en) Novel immunoregularory peptides,compositions and uses thereof
EP2186647A4 (en) IRON AND FILE FOLDER THEREFOR
GB0612917D0 (en) Metallic compositions,preparations and uses
EP2186646A4 (en) IRON AND FILE FOLDER THEREFOR
GB0616621D0 (en) Mite composition, composition use and methods
GB0720489D0 (en) Novel mixtures, compositions and ususe